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Abstract
Introduction:  The  vehicle  for  propofol  in  1  and  2%  solutions  is  soybean  oil  emulsion  10%,  which
may cause  pain  on  injection,  instability  of  the  solution  and  bacterial  contamination.  Formula-
tions have  been  proposed  aiming  to  change  the  vehicle  and  reduce  these  adverse  reactions.
Objectives:  To  compare  the  incidence  of  pain  caused  by  the  injection  of  propofol,  with  a  hypoth-
esis of  reduction  associated  with  nanoemulsion  and  the  occurrence  of  local  and  systemic  adverse
effects with  both  formulations.
Method:  After  approval  by  the  CEP,  patients  undergoing  gynecological  procedures  were  included
in this  prospective  study:  control  (n  =  25)  and  nanoemulsion  (n  =  25)  groups.  Heart  rate,  non-
invasive blood  pressure  and  peripheral  oxygen  saturation  were  monitored.  Demographics  and
physical condition  were  analyzed;  surgical  time  and  total  volume  used  of  propofol;  local  or
systemic  adverse  effects;  changes  in  variables  monitored.  A  value  of  p  <  0.05  was  considered
signiﬁcant.
Results: There  was  no  difference  between  groups  regarding  demographic  data,  surgical  times,
total volume  of  propofol  used,  arm  withdrawal,  pain  during  injection  and  variables  monitored.
There was  a  statistically  signiﬁcant  difference  in  pain  intensity  at  the  time  of  induction  of
anesthesia,  with  less  pain  intensity  in  the  nanoemulsion  group.
Conclusions:  Both  lipid  and  nanoemulsion  formulations  of  propofol  elicited  pain  on  intravenous
injection;  however,  the  nanoemulsion  solution  elicited  a  less  intense  pain.  Lipid  and  nanoemul-
sion propofol  formulations  showed  neither  hemodynamic  changes  nor  adverse  effects  of  clinicala  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
relevance.
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Avaliac¸ão  comparativa  do  propofol  em  nanoemulsão  com  solutol  e  com  lecitina  de
soja  para  anestesia  geral
Resumo
Introduc¸ão:  O  veículo  do  propofol  em  soluc¸ões  a  1  e  2%  é  a  emulsão  de  óleo  de  soja  a  10%,  que
pode provocar  dor  à  injec¸ão,  instabilidade  da  soluc¸ão  e  contaminac¸ão  bacteriana.  Formulac¸ões
foram propostas  com  o  objetivo  de  alterar  o  veículo  e  reduzir  essas  reac¸ões  adversas.
Objetivos:  Comparar  a  incidência  de  dor  à  injec¸ão  do  propofol  com  a  hipótese  de  reduc¸ão
associada à  nanoemulsão  e  a  ocorrência  de  efeitos  adversos  locais  e  sistêmicos  com  as  duas
formulac¸ões.
Método: Após  aprovac¸ão  pelo  Conselho  de  Ética  em  Pesquisa,  foram  incluídos  neste  estudo
prospectivo  pacientes  submetidas  a  procedimentos  cirúrgicos  ginecológicos:  grupos  controle
(n =  25)  e  nanoemulsão  (n  =  25).  Foram  monitorados  frequência  cardíaca,  pressão  arterial  não
invasiva e  saturac¸ão  periférica  de  oxigênio.  Foram  analisados  dados  demográﬁcos  e  estado
físico; tempo  cirúrgico  e  volume  total  usado  de  propofol;  efeitos  adversos  locais  ou  sistêmicos;
alterac¸ões nas  variáveis  de  monitoramento.  Considerou-se  signiﬁcativo  valor  de  p  <  0,05.
Resultados:  Não  houve  diferenc¸a  entre  os  grupos  em  relac¸ão  a:  dados  demográﬁcos,  tempos
cirúrgicos,  volume  total  usado  de  propofol,  retirada  do  brac¸o,  presenc¸a  de  dor  durante  a  injec¸ão
e variáveis  de  monitoramento.  Veriﬁcou-se  diferenc¸a  estatística  signiﬁcativa  na  intensidade  da
dor no  momento  da  induc¸ão  da  anestesia,  com  menor  intensidade  no  grupo  nanoemulsão.
Conclusões:  Ambas  as  formulac¸ões  de  propofol,  lipídica  e  em  nanoemulsão,  elicitaram  dor  à
injec¸ão venosa,  porém  a  soluc¸ão  de  nanoemulsão  promoveu  dor  em  menor  intensidade.  O  propo-
fol lipídico  e  o  propofol  em  nanoemulsão  não  apresentaram  alterac¸ões  hemodinâmicas  e  efeitos
adversos  de  relevância  clínica.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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fter  many  years  of  research  for  new  intravenous  drugs  for
se  in  anesthesia,  the  pharmaceutical  industry  has  seen  in
ropofol  (ICI  35868)  a  potential  anesthetic  agent.  During  the
tudy  preclinical  phase,  the  formulation  with  Cremophor  EL,
ommonly  used  in  the  pharmaceutical  industry,  has  been
roposed.1 Due  to  the  frequent  occurrence  of  hypersensitiv-
ty  reactions  and  injection  pain,  Cremophor  EL  formulation
as  abandoned  and  the  search  for  a  viable  formulation  was
nitiated  with  the  use  of  lipid  emulsions.  Lipid  emulsions
etermine  an  increase  in  onset  time,  decrease  in  potency,
nd  increase  in  awakening  time  relative  to  the  initial  for-
ulation  in  Cremophor  EL.2 In  an  attempt  to  improve  the
imitations  of  propofol  lipid  emulsion,  injection  pain,  and
otential  bacterial  growth,  formulations  have  been  made
ith  greater  concentration  of  propofol;  less  than  10%  oil;
hospholipids  modiﬁcations  within  the  emulsion  (containing
ifferent  fatty  acids)  and  emulsion  droplets  with  proteins.3
Nanoemulsions  have  been  associated  with  improvement
n  formulation  stability,  which  increases  the  useful  life  of
ropofol,  reduces  the  amount  of  free  propofol  and  therefore
ay  decrease  the  incidence  of  injection  pain,  in  addition  to
 wide  antimicrobial  spectrum.4,5
In  search  for  nanoemulsions  with  more  safety  features
nd  lower  risk  of  anaphylaxis,  polyethylene  glycol-660-
idroxiesterato  (Solutol® HS15  --  BASF,  Ludwigshafen,
ermany)  was  developed,  a  water-soluble  nonionic  solubi-
izer  for  parenteral  use  with  lipophilic  drugs  and  vitamins.
p
a
m
tt  contains  about  70%  of  lipophilic  molecules  and  30%  of
ydrophilic  molecules,  so  it  is  stable  and  has  been  used  in
arenteral  solutions.6,7
Thus,  taking  into  consideration  that  propofol  is  the
ntravenous  anesthetic  most  commonly  used  in  general  anes-
hesia  worldwide,  its  use  still  has  limitations  due  to  adverse
ffects,  and  there  are  few  studies  comparing  conven-
ional  propofol  with  propofol  nanoemulsion.  We  conducted  a
omparative  evaluation  between  propofol  formulations  tra-
itionally  used  (soy  lecithin  and  nanoemulsion  with  solutol)
n  gynecological  procedures.  The  objective  of  this  study  was
o  compare  the  incidence  of  propofol  injection  pain,  with  a
ypothesis  of  reduction  associated  with  nanoemulsion,  and
he  occurrence  of  local  and  systemic  adverse  effects  with
oth  formulations.
ethods
fter  approval  by  the  institutional  Research  Ethics  Com-
ittee,  a prospective,  open,  randomized  and  comparative
tudy  was  initiated,  which  included  50  patients  undergoing
ynecological  procedures  in  the  Department  of  Obstetrics
nd  Gynecology.
The  sample  size  calculation  was  based  on  a  previous
tudy,8 which  reported  incidence  of  pain  in  about  80%  of
atients  who  received  propofol  in  lipid  formulation.9,10 To
chieve  a  50%  reduction  in  the  incidence  of  pain,  the  sample
inimum  size  was  calculated  at  46  patients  for  chi-square
est,  with  a  degree  of  freedom  equal  to  one  (Table  1),  test
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Table  1  Study  population  demographic  data.
GCONT GNE p
n  =  23  n  =  25
Age  (years)
Mean  ±  SD  44.0  ±  12.3  41.3  ±  12.2  0.4448a
Minimum--maximum  20--69  19--72
Weight (kg)
Mean  ±  SD  60.1  ±  6.1  61.3  ±  7.2  0.4194a
Minimum--maximum 49--73  48--75
Height (m)
Mean  ±  SD 1.59  ±  0.07 1.59  ±  0.07 0.9712a
Minimum--maximum  1.45--1.75  1.42--1.72
BMI (kg  m−2)
Mean  ±  SD  23.9  ±  2.2  24.2  ±  3.1  0.369a
Minimum--maximum  18.9--27.8  18.7--29.8
Physical status
ASA  I 15  (65.2%) 15  (60%)  0,7761b
ASA  II 8  (34.8%) 10  (40%)
GCONT, control group; GNE, nanoemulsion group; BMI, body mass index; p, signiﬁcance of the statistical test used.
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-a Unpaired t-test.
b 2 test.
power  of  80%,  and  signiﬁcance  level  of  5%.  It  was  decided
to  use  50  patients  to  compensate  for  possible  losses.
Patients  undergoing  gynecological  laparoscopic  proce-
dures  and  breast  surgery,  aged  ≥18  years,  ASA  physical
status  I  and  II  (according  to  the  American  Society  of  Anes-
thesiologists  classiﬁcation),  BMI  >18.5  and  <30.0  kg  m−2 were
included  in  the  study.  Exclusion  criteria  were  patients  with
history  of  dyslipidemia  and  post-anesthesia  nausea  and
vomiting,  atopy,  use  of  psychoactive  drugs,  and  pregnancy.
After  obtaining  written  informed  consent,  patients  were
numbered  and  distributed  according  to  the  list  of  random
numbers,  at  a  ratio  of  1:1,  into  two  groups:  control  group
(Cont)  with  25  patients  who  received  propofol  with  lecithin
soy;  nanoemulsion  group  (NE)  with  25  patients  who  received
propofol  nanoemulsion.
Propofol  concentration  was  1%  in  both  the  conventional
soy  lecithin  and  nanoemulsion.
A blind  study  was  not  possible  because  the  drugs  used
in  the  study  had  different  organoleptic  properties  (propofol
in  nanoemulsion  is  transparent  and  stable  at  room  tempera-
ture,  while  propofol  in  soybean  lecithin  is  milky  and  requires
cold  storage).
Both  groups  received  identical  care  and  attention,  as  well
as  monitoring  and  anesthetic  technique,  except  for  the  drug
used.  The  patients  received  no  premedication.
In  the  operating  room,  venous  access  was  established  in
preferred  upper  limb  by  a  20G  Teﬂon  device,  and  hydra-
tion  was  started  with  lactated  Ringer  solution.  Subsequently,
patients  were  monitored  with  heart  rate  (HR),  electrocar-
diogram  (ECG),  noninvasive  systolic  blood  pressure  (SBP)  and
diastolic  blood  pressure  (DBP),  peripheral  oxygen  saturation
(SpO2),  and  bispectral  index  (BIS).
Initial  oxygenation  was  performed  with  100%  O2 via
face  mask  and  at  that  time  intravenous  induction  was
initiated  with  sequential  administration  of  the  following
t
t
srugs:  remifentanil,  propofol  or  propofol  nanoemulsion,  and
tracurium.  The  doses  used  for  induction  of  anesthesia  were
eft  to  the  clinical  anesthesiologist  discretion,  without  pro-
ocol  interference.  The  hemodynamic  changes  caused  by
ormulations  at  doses  commonly  used  in  clinical  practice
ere  recorded.
Induction  time  was  considered  from  the  end  of  drug  injec-
ion  until  BIS  values  fall  below  60.
After  tracheal  intubation,  patients  were  maintained
n  mechanical  ventilation  in  semi-closed  loop  system,
ith  2  L  min−1 ﬂow  and  ventilated  with  a  mixture  of
xygen/nitrous  oxide  (50:50),  with  adjusted  ventilatory
arameters  from  current  volume  (CV)  =  8--10  mL  kg−1,  end-
xpiratory  pressure  of  zero,  and  respiratory  rate  (RR)  to
aintain  (PETCO2) between  28  and  35  mmHg  with  SpO2 above
5%.
Anesthesia  was  maintained  with  remifentanil,  propofol
r  propofol  nanoemulsion  modiﬁed  with  an  infusion  pump
peed,  if  necessary,  to  maintain  BIS  values  between  40  and
0.  After  the  end  of  anesthesia,  the  patients  were  taken  to
he  post-anesthesia  care  unit  and  discharged  to  the  ward
ith  Aldrete-Kroulik  modiﬁed  index  ≥8.
The  analyzed  variables  were:
 Age,  weight,  height,  body  mass  index  (BMI),  and  ASA  phys-
ical  status;
 Surgical  time  and  total  volume  used  of  propofol  and  propo-
fol  nanoemulsion;
 Adverse  effects  at  the  injection  site:
•  Injection  pain.During  injection  of  propofol,  the  attempt  to  withdraw
he  arm  was  assessed  (yes/no)  and  the  patient  was  asked
o  evaluate  the  injection  pain,  according  to  the  verbal  pain
cale  of  four  terms  (absent,  mild,  moderate,  and  severe).
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Table  3  Evaluation  of  pain  and  other  adverse  events  in  the
ward,  12  h  after  anesthesia.
GCONT (n  =  23)  GNE (n  =  25)  Test
Pain  during  injection
No  10  43.5% 16  64% 2 =  1.29
Yes 13  56.5%  9  36%  p  =  0.2561
Severity  of  pain  during  injection
Absent  10  43.5%  16  64%  2 =  2.51
Mild 8  34.8%  6  24%  p  =  0.6110
Moderate  3  13.0%  2  8%
Severe  2  8.7%  1  4%
Inﬂammatory  signs
Absent  23  100%  25  100%
Postoperative  nausea  and  vomiting
No  20  87%  23  92%  2 =  0.01
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Twelve  hours  after  the  puncture,  the  patient  was  asked
f  she  felt  pain  during  injection.  If  so,  the  degree  of  pain
as  evaluated  using  the  verbal  scale  of  four  terms  (absent,
ild,  moderate,  and  severe).
 Adverse  effects:
•  Signs  of  infection  at  the  puncture  site;
•  Nausea  and  vomiting  after  the  procedure  (assessed  up
to  discharge  from  post-anesthesia  care  unit);
•  Heart  rate,  systolic  blood  pressure,  diastolic  blood  pres-
sure,  and  peripheral  oxygen  saturation  (every  10  min);
 Time  and  doses  of  induction  and  maintenance.
Statistical  analysis  was  performed  with  the  aid  of  the
oftware  SPSS  (Statistical  Package  for  Social  Sciences)  for
indows  10.  Student’s  t-test  or  the  Mann--Whitney  test  was
sed  to  compare  quantitative  variables  between  groups,
ccording  to  sample  distribution.  A  p-value  <  0.05  was  con-
idered  statistically  signiﬁcant.
esults
rom  the  initial  sample  of  50  patients,  48  were  included
n  the  present  study:  23  in  control  group  (GCONT)  and  25  in
anoemulsion  group  (GNE).  Two  patients  were  excluded  for
CONT due  to  surgical  complications.
There  was  no  difference  between  groups  regarding  age,
ender,  weight,  height,  BMI,  and  ASA  variables.  There  was  no
tatistically  signiﬁcant  difference  between  groups  (p  >  0.05)
Table  2).  Surgical  procedure  times  were  similar  in  both
roups:  3.02  h  for  GCONT and  2.50  h  for  GNE (p  =  0.4893).
There  was  no  signiﬁcant  difference  between  groups
egarding  arm  withdrawal  during  the  injection  of  propo-
ol  and  presence  of  pain  during  injection,  but  there  was  a
tatistically  signiﬁcant  difference  in  pain  severity  (p  =  0.01)
Table  2).
The  mean  total  volume  used  of  propofol  (GCONT)  was
6.70  ±  26.09  mL  and  propofol  nanoemulsion  (GNE) was
2.93  ±  37.77  mL.  There  was  no  statistically  signiﬁcant  dif-
erence  between  the  two  groups  (p  =  0.1521).
There  was  no  signiﬁcant  difference  in  prevalence  and
everity  of  pain  at  the  injection  site,  assessed  at  12  hours
Table  2  Distribution  of  patients  regarding  arm  withdrawal
during  propofol  injection,  presence  and  severity  of  pain  dur-
ing injection,  assessed  at  the  time  of  induction  of  anesthesia.
GCONT GNE Test
Arm  withdrawal  during  injection
No 17  73.9%  23  92%  2 =  2.82
Yes 6  26.1%  2  8%  p  =  0.09
Pain  during  injection
No  5  21.7%  12  48%  2 =  3.61
Yes 18  78.3%  13  52%  p  =  0.07
Severity  of  pain  during  injection
Absent  5  21.7%  12  48%  2 =  6.56
Mild 6  26.1%  8  32%  p  =  0.01
Moderate  7  30.4%  5  20%
Severe  5  21.7%  0  0%
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fter  venipuncture,  in  the  ward  (56.5%  in  GCONT and  36.0%
n  GNE).  It  was  mild  in  both  GCONT and  GNE,  34%  and
4.0%,  respectively.  No  patient  showed  signs  of  inﬂammation
Table  3).
Five  patients  (3  in  GCONT and  2 in  GNE) had  postopera-
ive  nausea  and  vomiting  (2 --  p  =  0.9215)  (Table  3).  Five
atients  (2  in  GCONT and  3  in  GNE)  had  systemic  adverse  events
2 --  p  =  0.9215):  two  patients  in  each  group  had  mild  skin
ash  and  one  patient  in  GNE had  moderate  bronchospasm
nd  wheezing.  There  was  no  signiﬁcant  difference  between
roups  regarding  HR,  SBP,  DBP,  and  SpO2 at  all  assessed  times
unpaired  t-test  --  p  >  0.05)  (Figs.  1  and  2).
iscussion
lthough  the  success  of  propofol  is  indisputable,  an  ideal
ormulation  which  eliminates  the  adverse  reactions  resulting
rom  lipid  formulations  is  investigated  until  the  present  day.
here  are  few  studies  comparing  the  propofol  nanoemulsion
7,8nd  classical  lipid  formulations, which  led  to  the  present
tudy  in  which  48  patients  undergoing  gynecological  proce-
ures  were  evaluated  in  order  to  identify  speciﬁc  clinical
eatures,  such  as  propofol  injection  pain  and  presence  of
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Figure  1  Heart  rate  evolution  in  both  groups.
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22Figure  2  Systolic  and  diastolic  blood  pressure  evolution  in
both groups.
local  and  systemic  adverse  events  associated  with  the  use
of  propofol  nanoemulsion.  They  were  compared  with  those
related  to  the  administration  of  propofol  in  lipid  emulsion
(conventional  propofol).
Although  several  preparations  of  propofol  were  tested,
a  preparation  that  reduces  the  incidence  of  pain  after
injection  has  not  been  found  yet.  Because  it  belongs  to
a  group  of  phenols  with  chemical  stability  and  low  tox-
icity,  but  with  the  potential  to  cause  skin,  endothelium,
and  mucous  membranes  irritation,  it  is  expected  but  not
desired  that  propofol  injection  causes  pain.  In  this  study,  the
incidence  of  propofol  injection  pain  assessed  at  the  injec-
tion  time  was  lower  in  nanoemulsion  group  (GNE)  than  in
control  group,  without  statistical  signiﬁcance  (GNE =  56.0%
versus  GCONT =  78.3%).  Regarding  arm  withdrawal  frequency
during  propofol  injection,  there  was  no  statistical  differ-
ence  (GNE =  8.0%  versus  GCONT =  26.1%).  Regarding  injection
pain  severity,  mild,  moderate,  and  severe  pain  were  more
frequent  in  GCONT,  p  =  0.01.  However,  in  both  assessments,
pain  incidence  and  arm  withdrawal  frequency  at  propofol
injection  time,  the  differences  were  clinically  signiﬁcant
and  p-values  (0.07  and  0.09)  suggest  that,  if  the  sam-
ple  were  larger,  statistical  difference  would  have  been
found.
In  the  same  study,  the  incidence  of  propofol  injection
pain  assessed  12  h  after  puncture  was  lower  in  nanoemulsion
group  than  in  the  control  group,  without  statistical  signiﬁ-
cance  (GNE =  36.0%  versus  GCONT =  56.5%),  as  well  as  injection
pain  severity.
Only  two  studies  were  found  in  the  literature  that  also
compared  the  classical  soy  lecithin  versus  nanoemulsion
formulations  of  propofol  used  in  this  study.7,8 Sudo  et  al.7
evaluated  the  incidence  of  pain  in  mice  receiving  intraperi-
toneal  infusion  of  acetic  acid  and  lipid  vehicle  of  propofol
and  non-lipid  nanoemulsion  (same  as  that  used  in  this  study).
Acetic  acid  and  lipid  vehicle  of  propofol  caused  pain  after
intraperitoneal  injection.  However,  there  was  no  pain  after
the  administration  of  propofol  nanoemulsion.  In  the  study
by  Rodrigues  et  al.8,  with  patients  undergoing  sedation  for
endoscopy,  the  incidence  of  propofol  nanoemulsion  injec-
tion  pain  (same  formulation  used  in  this  research)  was  lower
than  with  the  use  of  conventional  propofol,  with  statistical
signiﬁcance  (53.3%  vs.  82.7%).
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Other  studies  with  different  formulations  showed  dif-
erent  results,  such  as  the  research  that  found  higher
ncidence  of  pain  with  the  non-lipid  formulation  of  propofol
Cleofol®;  Themis  Medicare,  India)  than  with  propofol  emul-
ion  with  medium  chain  triglycerides  (Propofol-Lipuro®,  B
raun,  Germany).9 It  is  worth  mentioning  that  the  lipid
mulsion  propofol  used  in  this  study  was  different  from
hat  used  in  the  cited  publication.  Previous  studies  have
ound  that  formulations  with  medium  chain  triglycerides
ave  lower  free  fraction  of  propofol  and  hence  tendency
o  a  lower  incidence  of  pain.10--14
Sim  et  al.,15 in  a  study  that  comparatively  assessed
he  level  of  plasma  bradykinin  after  intravenous  injec-
ion  of  0.9%  saline  solution,  lipid  emulsion  propofol,
ropofol  microemulsion,  and  polyethylene  glycol-660-
idroxiestearato  (Solutol® HS15),  showed  higher  levels  with
he  injection  of  microemulsion  and  solutol  not  related  to
ncreased  incidence  of  pain.  Thus,  the  authors  propose  that
he  onset  of  pain  after  propofol  injection  is  not  entirely
elated  to  the  bradykinin  release.
The  application  of  lidocaine,  strategy  widely  used  to
educe  pain  on  injection  of  propofol,  has  been  discussed.
im  et  al.15 reported  that  there  was  no  change  in  free
ropofol  concentration  during  the  aqueous  phase  after  lido-
aine  addition;  while  Yamakage  et  al.14 reported  that  there
as  a  change  of  pH  and  stability  of  the  solution  with  the
idocaine  addition,  suggesting  that  lidocaine  administered
efore  propofol  may  inhibit  transmission  of  pain  through
ndothelial  free  nerve  endings.
Although  the  assessment  of  surgical  time  and  total  vol-
me  used  of  propofol  has  not  been  part  of  the  objectives
f  this  study,  these  data  were  analyzed  and  are  part  of  the
esults  because  statistically  signiﬁcant  differences  in  any  of
hem  or  both  could  create  a  bias  in  interpreting  the  results
f  adverse  events.
There  were  no  signs  of  inﬂammation  at  the  injection  site
n  any  patient,  which  may  occur  in  1--5%  of  the  cases.16
It  has  been  widely  reported  in  the  literature  that  intra-
enous  administration  of  propofol  may  lead  to  decreased
lood  pressure  with  little  change  in  heart  rate  and
hythm,17--21 which  is  conﬁrmed  in  this  study  that  found  sim-
lar  reduction  of  SBP  and  DBP  values  in  both  groups  only  at
nduction  time,  with  posterior  stability,  with  minimum  toler-
ble  values.  Rodrigues  et  al.,8 in  humans,  and  Sudo  et  al.7 in
ice,  both  used  lipid  or  nanoemulsion  propofol  and  reported
eduction  in  systolic  and  diastolic  arterial  pressures,  with
o  difference  between  the  analyzed  groups.  Heart  rate
lso  decreased  at  the  time  of  induction  in  both  groups,
ith  subsequent  stabilization,  without  reaching  critical
evels.
In  the  present  study,  few  cases  of  nausea/vomiting  were
bserved  after  surgery  (GNE =  8.0%  versus  GCONT =  13.0%),
ith  no  statistical  difference  between  the  drugs  used,
hich  conﬁrms  the  literature  reporting  that  propofol  has
ntiemetic  property,  by  antidopaminergic  activity,  with
epressant  effect  on  the  chemoreceptor  trigger  zone  and
agal  nuclei,  lower  release  of  glutamate  and  aspartate  in
he  olfactory  cortex,  and  decreased  serotonin  in  the  area
ostrema.
Both  formulations  of  propofol,  lipid  and  nanoemulsion,
aused  intravenous  injection  pain,  but  the  nanoemulsion
olution  promoted  less  intense  pain.  Propofol  in  lipid
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mulsion  and  propofol  in  nanoemulsion  showed  no
emodynamic  changes  and  adverse  effects  of  clinical
elevance.
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